Sunday, December 01, 2013 3:06:09 PM
Nov 27, 2013 (ACCESSWIRE via COMTEX) -- New York, November 27, 2013
Moving notably higher on the session are shares of beaten down pain management company Zalicus Inc ZLCS -2.42% . Volume is already more than double the 10-day average in the name.Still, the shares are ~75% below where they traded before news hit that Z160 did not meet its primary endpoint in two Phase 2 trials. The company is now pinning its hopes on Z944.Here's SA contributor Jason Napodano: "I spoke with management. Talked about a number of reasons why Z944 is different from Z160. Will share soon."
http://www.wired.com/gadgetlab/2012/08/apple-amazon-mat-honan-hacking/
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM